BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310

Reuters
21 Nov 2024
BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310

Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O:

  • LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRST COHORT IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS, ADVANCING TO NEXT DOSE GROUP

  • LIPELLA PHARMACEUTICALS INC - TRIAL EXPECTED TO CONCLUDE BY MID-2025 WITH TOP-LINE DATA BY YEAR-END 2024

Source text: ID:nGNX6JCkwl

Further company coverage: LIPO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10